Anzeige
Erschienen in:
01.10.2012 | Original article
Magnifying endoscopy with narrow-band imaging helps determine the management of gastric adenomas
Erschienen in: Gastric Cancer | Ausgabe 4/2012
Einloggen, um Zugang zu erhaltenAbstract
Background
There are no clear clinical criteria for the management of gastric lesions diagnosed as adenomas (Vienna classification category 3) by pre-treatment biopsy. In the present study, we examined the feasibility of magnifying endoscopy with narrow-band imaging (ME–NBI) in discriminating early gastric cancers (Vienna classification category 4 or 5) from adenomas in lesions diagnosed as adenomas by pre-treatment biopsy.
Methods
This was a single-center cross-sectional retrospective study at a tertiary referral center. One hundred thirty-seven consecutive cases of gastric lesions diagnosed as adenomas in pre-treatment forceps biopsy were examined with conventional non-magnifying endoscopy under white light, non-magnifying chromoendoscopy, and ME–NBI. We investigated the association between the final pathological diagnoses (carcinoma or adenoma) and the following factors: lesion size (mm), color (red or white), macroscopic type (depressed or others), presence of ulceration, and positive ME–NBI finding. The presence of an irregular microvascular pattern or an irregular microsurface pattern with a demarcation line between the lesion and the surrounding area was regarded as a positive ME–NBI finding.
Results
Lesion size was significantly larger in carcinomas than adenomas (P = 0.005). Depressed lesion (P = 0.011), red color (P < 0.001), and positive ME–NBI finding (P < 0.001) were significant predictive factors for carcinoma. Multivariate logistic regression confirmed that red color (odds ratio [OR] 3.04, 95% confidence interval [CI] 1.26–7.34, P = 0.14) and a positive ME–NBI finding (OR 13.68, 95% CI 5.69–32.88, P < 0.001) were independent predictive factors for carcinomas. A positive ME–NBI finding was the strongest predictive factor.
Conclusions
ME–NBI is useful in planning the management of lesions diagnosed as adenomas by pre-treatment forceps biopsy.